Drug Database
IN

indapamide (indapamide, Douglas)

✓ Approved

Douglas Pharmaceuticals Limited · SLC12A3 · 小分子

什么是 indapamide?

indapamide 是一种小分子,由Douglas Pharmaceuticals Limited研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名indapamide, Douglas
公司Douglas Pharmaceuticals Limited
药物类别小分子
分子靶点SLC12A3
给药途径Oral (PO)
状态Approved

作用机制

分子靶点

indapamide 作用于 1 个分子靶点:

SLC12A3solute carrier family 12 member 3 (NCCT, NCC)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

indapamide 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Vascular disordersHypertension✓ Approved

相关研究文献

PubMedToxicology reports2026-11-16

Refractory circulatory shock following intentional polypharmacy antihypertensive and NSAID overdose: Clinical recovery temporally associated with sequential intravenous lipid emulsion and methylene blue - A case report.

Danial Syed Hussain SH, Honan David Michael DM

Calcium channel blocker (CCB) overdose carries substantial mortality without advanced organ support. Ingestion of a fixed-dose antihypertensive combination with a non-steroidal anti-inflammatory drug (NSAID) is an uncommon polypharmacy toxidrome. The role of intravenous lipid emulsion (ILE) and methylene blue in refractory cases remains poorly defined. A 64-year-old man (135 kg) ingested approximately 300 mg amlodipine, 300 mg perindopril, 75 mg indapamide and 15,000 mg naproxen with ethanol. Despite apparent stability on arrival he deteriorated to 77/47 mmHg, pH 7.20 and lactate 10.5 mmol/L. Seven hours of escalating treatment - noradrenaline (peak 58 mcg/min), vasopressin, calcium and high-dose insulin euglycaemic therapy (HIET) - failed to restore haemodynamic targets. Intralipid 20% was given (total approximately 8.9 mL/kg), followed 35 min later by methylene blue 140 mg (1.0 mg/kg). Lactate fell from 10.5 to 6.1 mmol/L over the subsequent 55 min with the noradrenaline dose unchanged. All vasopressors were stopped within 14 h. HIET was accompanied by concurrent glucose, potassium and phosphate nadirs (1.7, 1.7 and 0.27 mmol/L). KDIGO stage 2 acute kidney injury (peak creatinine 303 µmol/L) required no renal replacement therapy and resolved completely (creatinine 81 µmol/L at 3.5 months). The patient was discharged on day 9. Sequential ILE and methylene blue were temporally associated with rapid metabolic recovery in refractory circulatory shock following polypharmacy antihypertensive overdose. Individual contributions cannot be determined from a single case, and a delayed effect of concurrent HIET cannot be excluded. These agents may represent rescue options when conventional therapy is insufficient.

PMID 43036329
阅读全文 →
PubMedAmerican journal of cardiovascular drugs : drugs, devices, and other interventions2026-10-22

Beyond Conventional Antihypertensives: RNA Interference, Endothelin Antagonism, and Aldosterone-Synthase Inhibition in the Current Therapeutic Landscape.

Gaudio Giovanni Vincenzo GV, Derosa Giuseppe G, De Angelis Giuseppe G, Tremamondo John J et al.

Hypertension is the leading modifiable cardiovascular risk factor, yet long-term adherence to antihypertensive therapy remains suboptimal. RNA-based approaches targeting hepatic angiotensinogen (AGT) have emerged as an attractive strategy for upstream renin-angiotensin-aldosterone system suppression and warrant a timely, focused review of the field. PubMed/MEDLINE, ClinicalTrials.gov and the most relevant scientific and academic databases were searched up to February 2026 to draft a narrative review of peer-reviewed clinical trials, pivotal translational studies, contemporary hypertension guidelines, and official regulatory documents relevant to innovative antihypertensive treatments, such as antisense AGT suppression (zilebesiran), endothelin antagonism (aprocitentan), and aldosterone-synthase inhibition (baxdrostat). Zilebesiran demonstrated durable blood-pressure lowering in monotherapy (KARDIA-1: placebo-adjusted ambulatory systolic blood pressure (BP) - 16.7 mmHg at month 3) and as add-on therapy (KARDIA-2: greatest effect with indapamide background). KARDIA-3 extended evaluation to a higher-risk, heavily medicated population, in which the primary endpoint was not met. The ongoing ZENITH outcomes trial will determine whether AGT silencing reduces hard cardiovascular end-points. Aprocitentan reduced office and ambulatory systolic BP in resistant hypertension (PRECISION trial) and has received regulatory approval in the USA, EU, and UK, with specific monitoring requirements for fluid retention and hematological effects. Baxdrostat demonstrated selective aldosterone-synthase inhibition with meaningful BP reductions across two phase II trials. RNA interference targeting AGT represents one of the most advanced disease-modifying platforms in hypertension, alongside the already-approved endothelin antagonism and the emerging aldosterone synthase inhibition strategy. The available evidence supports cautious optimism and continued translational investment, but not premature adoption into routine practice.

PMID 42907726
阅读全文 →
PubMedEuropean heart journal. Cardiovascular pharmacotherapy2026-09-15

Real-world analysis of adherence, persistence, and outcomes in patients receiving four-drug antihypertensive therapy.

Mancia Giuseppe G, Brouwers Sofie S, Calabria Silvia S, Leogrande Melania M et al.

Describe real-world use, adherence, persistence, and risk of non-fatal cardiovascular events (CVE) and mortality among patients receiving four-drug antihypertensive therapy. This was a retrospective, longitudinal cohort study of Italian administrative healthcare databases (N=7,160,298). Eligible patients were ≥18 years and received four-drug therapy between 2018 and 2022. Class- and molecule-level subcohort analyses required data for ≥1 year either side of four-drug therapy identification. Adherence and persistence were based on prescription availability. A Cox proportional hazards model was used for risk assessment.Among 228,594 eligible patients, 113,755 received either an angiotensin-converting enzyme inhibitor (ACEi; n=57,473) or angiotensin II receptor blocker (n=56,282), thiazide/thiazide-like diuretic (DIU), calcium channel blocker (CCB), and a fourth class (mostly beta-blockers [BBs]; n=87,022).In the Class subcohort (ACEi+DIU+CCB+BB; n=41,903), high adherence was more frequent among patients receiving two (52.1%) versus three (40.2%) or four (25.0%) pills (global P<0.001); persistence was also improved (P<0.02 from 6 months). Adherence and persistence were significantly higher with two versus three pills in the Molecule subcohort (perindopril, indapamide, amlodipine, and bisoprolol; n=8007). For persistent versus non-persistent patients, there was a risk reduction for CVE (12.4%; P<0.001) and mortality (16.4%; P<0.001) in the Class subcohort, with similar findings in the Molecule subcohort (20.9% [P=0.003] and 20.9% [P=0.002], respectively). In patients receiving four-drug antihypertensive therapy, adherence and persistence were significantly improved with lower pill burden. Persistence was associated with lower risks of CVE and mortality.

PMID 42736626
阅读全文 →
PubMedInternational journal of general medicine2026-09-06

Thiazide Diuretics Are Associated with a Higher Triglyceride-Glucose Index Than Calcium Channel Blockers in Hypertensive Patients.

Erarslan Sertas S, Acet Aycan A, Karagoz Osman Nurullah ON, Erkan Bugrahan B et al.

Hypertension is frequently accompanied by metabolic abnormalities that increase cardiovascular risk. The triglyceride-glucose (TyG) index is a practical surrogate marker of insulin resistance. This study aimed to compare TyG index values and related metabolic parameters between patients receiving RAAS blockers plus thiazide/thiazide-like diuretics and those receiving RAAS blockers plus calcium channel blockers (CCBs) as antihypertensive regimens. In this retrospective observational study, 157 of 189 screened patients met eligibility criteria and were included (RAAS blocker plus thiazide/thiazide-like diuretic, n=95; RAAS blocker plus CCB, n=62). Multivariable linear regression models and inverse probability of treatment weighting (IPTW) analyses were performed to assess the independence of findings from clinical confounders. The TyG index was significantly higher in the diuretic group than in the CCB group [9.21 (9.01-9.73) vs 8.95 (8.66-9.40); p<0.001], as were triglyceride [186.00 vs 142.35 mg/dL; p<0.001] and uric acid levels [5.70 vs 5.00 mg/dL; p=0.004]. Blood pressure control rates were similar. The treatment group effect remained significant across all adjusted models, including IPTW-weighted regression (β=0.385, p=0.0003). A significant treatment group × diabetes mellitus interaction was observed (p=0.042), suggesting a stronger association in diabetic patients. A dose-stratified analysis within the diuretic group showed a significant dose-response relationship: higher hydrochlorothiazide (25 vs 12.5 mg/day) and indapamide (2.5 vs 1.25 mg/day) doses were both associated with significantly higher TyG index, fasting glucose, and uric acid levels. In an exploratory diuretic subgroup analysis, urea and BUN levels were higher with hydrochlorothiazide than indapamide; however, this analysis was underpowered (indapamide n=24) and should be interpreted with caution. RAAS blocker plus thiazide/thiazide-like diuretic regimens were associated with a significantly higher TyG index and a less favorable metabolic profile than RAAS blocker plus CCB regimens, independent of multiple clinical confounders. Metabolic risk profiles should be considered when selecting antihypertensive combination therapy; prospective studies are needed to establish causality.

PMID 42701822
阅读全文 →
PubMedAmerican journal of cardiovascular drugs : drugs, devices, and other interventions2026-08-07

Adherence and Healthcare Costs Associated with Single-vs Free-Pill Combination of Perindopril-Based Antihypertensive Medications: An 11-Year Follow-Up, Real-World Evidence.

Savarese Gianluigi G, Vintila Ana-Maria AM, Degli Esposti Luca L, Dovizio Melania M et al.

Short-term studies have demonstrated that single-pill combinations (SPCs) improve adherence, reduce hypertension-related complications, and lower costs; however, long-term benefits remain unclear. This study compared adherence, healthcare resource utilization (HCRU), and costs over 11 years in patients treated with SPCs versus free-pill combinations (FPCs) of antihypertensive drugs in routine Italian practice. We analyzed a large administrative dataset (2010-2022) covering approximately 7 million Italian citizens. Adults initiating perindopril (PER)-based SPC or FPC with amlodipine and/or indapamide were included. PER-based therapies were selected because their SPCs were among the first marketed in Italy, allowing for extended follow-up. Adherence was measured by proportion of days covered (PDC), with high adherence defined as PDC ≥ 80%. Among 24,476 patients (mean age: 64.6 years; 59.7% male), 92.6% received SPCs, and 6.0% FPCs. High adherence was observed in 75.5% of SPC users compared with 32.0% of FPC users. SPC users had fewer all-cause hospitalizations and outpatient visits (both p < 0.001). Average annual healthcare costs were €242.96 lower for SPC users (95% CI €55.03-€430.89; p < 0.05), with significant reductions in costs related to all-cause and cardiovascular-related hospital admissions (p < 0.001). In this long-term, real-world study, SPC use was associated with better adherence, reduced HCRU, and lower healthcare costs compared with FPC regimens. These economic benefits were evident within 1 year and may yield substantial long-term savings for national health systems, given the high prevalence and chronic nature of hypertension.

PMID 42566123
阅读全文 →
PubMedInternational journal of hypertension2026-07-15

Real-World Effectiveness and Safety of Ramipril/Indapamide Combination Therapy in Essential Hypertension: A Retrospective Study on UK Primary Care Records.

Mogielnicki Mariusz M, Płaszczyca Marian M, Leary Andrew A, Piechaczek Mateusz M et al.

This study aimed to evaluate the patient characteristics, effectiveness, safety, adherence, and persistence of ramipril/indapamide (R/I) free combination therapy in patients with essential hypertension inadequately controlled with monotherapy. This retrospective observational cohort study used anonymized UK primary care electronic health records from IQVIA's Medical Research Database (IMRD), incorporating "The Health Improvement Network" (THIN), a Cegedim Database. Adults with essential hypertension who switched from ramipril or indapamide monotherapy to R/I between database inception and January 1, 2021, were enrolled. Outcomes included changes in systolic blood pressure (SBP) and diastolic blood pressure (DBP), proportions achieving BP < 140/90 mmHg or SBP ≥ 20 mmHg/DBP ≥ 10 mmHg decrease, proportion of days covered (PDC), persistence, and adverse events (AEs) over 12 months. A total of 1089 patients met inclusion criteria (mean age 63.5 years; 55.6% female). Mean baseline BP on monotherapy was 156.0/89.1 mmHg. Over 12 months, mean SBP decreased by 18.7 mmHg and DBP by 8.9 mmHg (both p < 0.001); 54.3% of patients achieved BP < 140/90 mmHg, and 61.6% met the predefined BP decrease threshold. A dose-response relationship was observed for BP outcomes. Mean PDC was 92.4% at 3 months and 86.2% at 12 months; persistence was 87.7% and 81.5%, respectively. The most frequent AE was cough (10.38%); gout occurred in 0.73%, exclusively in indapamide-naïve patients. The outcomes remained consistent across sensitivity and subgroup analyses. Switching from ramipril or indapamide monotherapy to their free combination was associated with clinically meaningful BP decreases, high adherence and persistence, and a favorable safety profile in routine practice. These findings are consistent with current therapeutic guidelines that endorse its use in essential hypertension management.

PMID 42453630
阅读全文 →

注册免费账户还可查看另外 1373 篇文献

免费注册查看全部文献 →

了解更多indapamide